Phase II Study of Denifanstat Looks to Add First-in-Class Agent to HER2+Breast Cancer Treatment Armamentarium

With the development of the first-in-class fatty acid synthase inhibitor denifanstat, which is being evaluated in a Phase II trial, investigators are hoping that the agent can be a key component in restoring sensitivity to standard treatments for patients with HER2- positive metastatic breast cancer, in addition to its antitumor properties.